SCHEMBL498671

SCHEMBL498671

CSc1ccc(C(=O)/C=C/c2cc(C)c(C(=O)O)c(C)c2OC(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
MEN1 O00255 3/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
HTT P42858 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29386613 1.00 PPARG (0.47) PPARGPPARDPPARAMEN1ALDH1A1
SCHEMBL29381267 0.90 PPARG (0.44) PPARGPPARDPPARAMEN1ALDH1A1
SCHEMBL498905 0.90 PPARG (0.44) PPARGPPARDPPARAMEN1ALDH1A1
SCHEMBL498781 0.89 PPARG (0.51) PPARGPPARDPPARAMEN1ALDH1A1
SCHEMBL3969812 0.88 CAPN1 (0.45) MAPTLMNARAB9ANPC1SMN1; SMN2
SCHEMBL3962833 0.88 PPARG (0.38) PPARGPPARDPPARAALDH1A1SMN1; SMN2
SCHEMBL29379677 0.87 PPARG (0.46) PPARGPPARDPPARAMEN1ALDH1A1
SCHEMBL498873 0.87 PPARG (0.46) PPARGPPARDPPARAMEN1ALDH1A1
SCHEMBL498833 0.87 MAPT (0.44) ALDH1A1MAPTLMNAGAANPC1
SCHEMBL3969980 0.87 CXCL12 (0.41) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350341-B1 METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS GENFIT (FR) 2021-08-11 EP claimed
US-10792277-B2 Methods of treatment of fibrosis and cancers GENFIT (FR) 2020-10-06 US claimed
US-10722575-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2020-07-28 US claimed
US-20190352715-A1 NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS GENFIT (FR) 2019-11-21 US claimed
US-10350181-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2019-07-16 US claimed
EP-2948137-B1 METHODS OF TREATMENT OF FIBROSIS AND CANCERS GENFIT (FR) 2018-11-14 EP claimed
US-10022343-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2018-07-17 US claimed
EP-2641596-B1 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2018-05-02 EP claimed
US-20170368007-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS GENFIT (FR) 2017-12-28 US claimed
US-9782373-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders GENFIT (FR) 2017-10-10 US claimed
WO-2011080276-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A DPP-4 INHIBITOR AND A 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE GENFIT (FR) 2011-07-07 WO claimed
US-7943661-B2 Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties GENFIT (FR) 2011-05-17 US claimed
US-7632870-B2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof GENFIT (FR) 2009-12-15 US claimed
US-7566737-B2 Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2009-07-28 US claimed
EP-1525177-B1 SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF GENFIT (FR) 2007-06-27 EP claimed
EP-1519908-B1 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF GENFIT (FR) 2007-06-13 EP claimed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US claimed
US-20050171149-A1 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof GENFIT (FR) 2005-08-04 US claimed
EP-1519908-A2 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF Genfit (FR) 2005-04-06 EP claimed
WO-2004005243-A2 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES GENFIT (FR) 2004-01-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170368007-A1 USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients PSEN1, BACE1, PSEN2 PPARG 17/4885PPARD 39/4885PPARA 69/4885
US-20190352715-A1 NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS FABP1, SLC10A1, FABP2 PPARG 381/4885PPARD 350/4885PPARA 391/4885
US-10722575-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-10350181-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885
US-20050171149-A1 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof BRCA1, LOXL1, APOL1 PPARG 88/4885PPARD 149/4885PPARA 81/4885
US-10792277-B2 Methods of treatment of fibrosis and cancers MMP1, COL1A1, MMP8 PPARG 344/4885PPARD 1060/4885PPARA 446/4885
US-10022343-B2 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders FABP1, GOT2, GOT1 PPARG 119/4885PPARD 94/4885PPARA 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.